Pre-exposure prophylaxis (PrEP) treatment has been around for a while now. So, it is not far-fetched to expect that most people in risk communities are aware of it. However, the story is not quite simple for Hispanics, where low PrEP awareness rates were noticed, according to a report released by the Centers for Disease Control and Prevention on Friday, October 8th.
The Morbidity and Mortality Weekly report disclosed that at least one in four Hispanic persons knows of PrEP, and one in five of those eligible for referral are referred to as PrEP providers. The report covered a study by Shubha Rao, M.P.H. from CDC Atlanta, and her colleagues.
The researchers analyzed the 2019 National HIV Prevention Program Monitoring and Evaluation HIV testing data. They examined PrEP awareness and referral among Hispanic persons. They found that 27% of the 310,954 people who tested positive for HIV at CDC-funded sites knew preexposure prophylaxis. However, out of the 111,664 persons who got HIV negative results and were eligible for referral, only 22% went to PrEP providers.
The result showed that PrEP awareness and referrals were lower for Hispanic individuals versus non-Hispanic whites. The significant differences were by age, gender, race, population, group, geographic region, and test setting. The researchers concluded that routinizing PrEP education and referrals, expanding coverage for PrEP medications and implementing culturally and linguistically relevant strategies might improve the equitable use of PrEP among Hispanic persons at risk of contracting HIV.
PrEP drugs like Truvada have contributed a lot in the fight to curb and end HIV/AIDS infections. But despite Truvada’s effectiveness, many users complained of severe adverse side effects and filed lawsuits against the manufacturer. You can file a suit, too, if your use of Truvada affected your health adversely.
For more information or a free case review, contact our experienced mass tort and class action attorneys right away.